{"analyses":[{"ciLowerLimit":"1.936","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.740","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"All analyses based on final DBL were descriptive only with p-values reported as nominal.","paramType":"Odds Ratio (OR)","paramValue":"2.691","statisticalMethod":"Stratified Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.1","upperLimit":"47.6","value":"42.3"},{"groupId":"OG001","lowerLimit":"17.3","upperLimit":"26.0","value":"21.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"355"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by IRC per RECIST 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab monotherapy","id":"OG000","title":"Cemiplimab"},{"description":"Participants received platinum-based doublet chemotherapy","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"FAS included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to 73.5 months","title":"Objective Response Rate (ORR) Per IRC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}